Last reviewed · How we verify
At increased risk of coronary heart disease
Approved treatments
- Tricor (Micronized) · Salix
Fenofibrate activates PPARα, enhancing lipolysis and reducing triglycerides, while increasing HDL-cholesterol and uric acid excretion.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- At increased risk of coronary heart disease patent landscape — cliff calendar, originator estates, attackable patents
- At increased risk of coronary heart disease treatment landscape brief
- At increased risk of coronary heart disease treatment updates RSS
Frequently asked questions about At increased risk of coronary heart disease
What drugs treat At increased risk of coronary heart disease?
Tracked treatments include Tricor (Micronized).
What is the treatment for At increased risk of coronary heart disease?
Standard treatment for At increased risk of coronary heart disease includes Tricor (Micronized). See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: At increased risk of coronary heart disease patent cliff · At increased risk of coronary heart disease CI report
- Treatment: Tricor (Micronized) · Salix
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing